Eran Shlomovitz

Eran Shlomovitz

Auto-generated profile, based on publicly available information

Eran Shlomovitz

University Health Network, Toronto General Hospital, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
ESEran Shlomovitz
Eran Shlomovitz
RPRadu Pescarus
Radu Pescarus
MCMaria A. Cassera
Maria A. Cassera
ASAhmed M. Sharata
Ahmed M. Sharata
KRKevin M. Reavis
Kevin M. Reavis
LSLee L. Swanström
Lee L. Swanström

15 September 2016 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
OCOscar M. Crespin
Oscar M. Crespin
LLLouis W. C. Liu
Louis W. C. Liu
APAmbica Parmar
Ambica Parmar
TJTimothy D. Jackson
Timothy D. Jackson
JHJemila Hamid
Jemila Hamid
AOAllan Okrainec
Allan Okrainec

15 August 2015 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
RPRadu Pescarus
Radu Pescarus
ESEran Shlomovitz
Eran Shlomovitz
ASAhmed M. Sharata
Ahmed M. Sharata
MCMaria A. Cassera
Maria A. Cassera
KRKevin M. Reavis
Kevin M. Reavis
LSLee L. Swanström
Lee L. Swanström

20 December 2022 in Annals of Surgery
Verified
Journal Article
Open access
SIShayan S. Irani
Shayan S. Irani
NSNeil Sharma
Neil Sharma
ASAndrew C. Storm
Andrew C. Storm
RSRaj J Shah
Raj J Shah
PCPrabhleen Chahal
Prabhleen Chahal
SMSchalk Van Der Merwe
Schalk Van Der Merwe
Objective: To evaluate the safety and efficacy of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS). Background: For patients with acute cholecystitis who are poor surgical candidates, EUS-GBD using a LAMS is an important treatment alternative to percutaneous gallbladder drainage. Methods: We conducted a regulatory-compliant, prospective multicenter trial at 7 tertiary referral centers in the United States of America and Belgium. Thirty consecutive patients with mild or moderate acute cholecystitis who were not candidates for cholecystectomy were enrolled between September 2019 and August 2021. Eligible patients had a LAMS placed transmurally with 30 to 60-day indwell if removal was clinically indicated, and 30-day follow-up post-LAMS removal. Endpoints included days until acute cholecystitis resolution, reintervention rate, acute cholecystitis recurrence rate, and procedure-related adverse events (AEs). Results: Technical success was 93.3% (28/30) for LAMS placement and 100% for LAMS removal in 19 patients for whom removal was attempted. Five (16.7%) patients required reintervention. Mean time to acute cholecystitis resolution was 1.6±1.5 days. Acute cholecystitis symptoms recurred in 10.0% (3/30) after LAMS removal. Five (16.7%) patients died from unrelated causes. Procedure-related AEs were reported to the FDA in 30.0% (9/30) of patients, including one fatal event 21 days after LAMS removal; however, no AEs were causally related to the LAMS. Conclusions: For selected patients with acute cholecystitis who are at elevated surgical risk, EUS-GBD with LAMS is an alternative to percutaneous gallbladder drainage. It has high technical and clinical success, with low recurrence and an acceptable AE rate. Clinicaltrials.gov, Number: NCT03767881.

1 January 2018 in Obstetrics and Gynecology International
Verified
Journal Article
Open access
YLYeh Chen Lee
Yeh Chen Lee
NJNazlin Jivraj
Nazlin Jivraj
COCatherine O’bRien
Catherine O’bRien
TCTanya Chawla
Tanya Chawla
ESEran Shlomovitz
Eran Shlomovitz
SLStephanie Lheureux
Stephanie Lheureux
Malignant bowel obstruction (MBO) is a major complication in women with advanced gynecologic cancers which imposes a significant burden on patients, caregivers, and healthcare systems. Symptoms of MBO are challenging to palliate and result in progressive decompensation of already vulnerable patients with limited therapeutic options and a short prognosis. However, there is a paucity of guidelines or innovative approaches to improve the care of women who develop MBO. MBO is a complex clinical situation that requires a multidisciplinary approach to ensure the appropriate treatment modality and interprofessional care to optimally manage these patients. This review summarizes the current literature on the different approaches targeting MBO management including surgical intervention, chemotherapy, total parenteral nutrition, and pharmacological treatment. In addition, the impact of MBO management on patients’ quality of life (QOL) is examined. This article focuses on the challenges in developing evidence-based treatment guidelines for MBO and barriers in clinical trial design for MBO and proposes strategies to advance the MBO management. Collaboration is essential to design studies that may improve the overall care and quality of life for these patients. Prospective data are needed to inform clinical practice, establish a new benchmark for evidence-based MBO management, and better understand the biology of MBO.

1 October 2005 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
ESEran Shlomovitz
Eran Shlomovitz
DQDouglas Quan
Douglas Quan
RERoya Etemad-Rezai
Roya Etemad-Rezai
VMVivian C. McAlister
Vivian C. McAlister